Hunt Investment Group
Hunt Growth Capital is the private equity division of Hunt Consolidated, Inc., focusing on direct investments and investments in other funds. The firm avoids sectors such as oil and gas, domestic U.S. real estate, and utilities. In its direct investments, Hunt Growth Capital targets growth capital, buyouts, and acquisitions in early middle-market companies, typically investing between $2 million and $6 million for minority stakes of 25% or more in companies with revenues ranging from $10 million to $25 million and EBITDA of up to $3 million. The firm is geographically diverse, preferring investments in the Southwest and Southeast U.S., while also considering opportunities in Western Europe and Japan for fund investments. For fund investments, Hunt Growth Capital generally invests between $1 million and $5 million in funds with at least $100 million in assets under management, although it may consider smaller funds in special circumstances. The firm aims to take active roles on the boards of its portfolio companies and prefers senior equity investments with shorter lock-up periods. Hunt Growth Capital is headquartered in Dallas, Texas.
Bitwise Industries
Series B in 2021
Bitwise Industries Inc. is a technology ecosystem company based in Fresno, California, focused on enhancing the local technology landscape. Established in 2013, the company operates Geekwise Academy, which provides accelerated coding education aimed at individuals of all ages, particularly from marginalized backgrounds. In addition to educational services, Bitwise Industries runs a custom software development firm, Shift3 Technologies, that connects experienced developers with entry-level programmers to create software solutions. The company also fosters community and collaboration by developing tech venues and co-working spaces that serve as hubs for technologists and technology companies. Through these initiatives, Bitwise Industries aims to empower individuals with vital tech skills and create pathways to meaningful careers in the technology sector.
Cudoni
Venture Round in 2020
Cudoni operates a leading online marketplace for pre-owned luxury goods in the UK and Europe, focusing on convenience and exceptional service for both consumers and businesses. The company manages the entire sales process, offering services such as item collection, data-driven market valuations, professional photography, and authentication. By handling these elements, Cudoni achieves higher selling prices for its clients, typically 30-50% more than if they sold their items independently. Additionally, Cudoni provides an 'Instant Purchase' option for those who prefer immediate transactions without the hassle of consignment. By exclusively controlling its inventory, the platform ensures that buyers have access to a curated selection of high-demand products, all guaranteed for authenticity and quality, with next-day delivery available. Cudoni's approach addresses the challenges of counterfeits in the luxury market, making the buying and selling of pre-loved luxury items more accessible and efficient.
Silverback Therapeutics
Series B in 2020
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.